https://www.selleckchem.com/pr....oducts/ulixertinib-b
Age, pathological subtype, sex, stage, β2-MG level, LDH level, and the using of rituximab were not correlated with the complete remission rate of the patients(P0.05), while the IPI score was correlated with the recent complete remission rate (P0.05). The median follow-up time was 19 (1-38) months, 10 patients survived, in which 6 cases were still in complete remission, and the median time to progression-free survival was 15 (1-38) months. The first symptom of primary bone diffuse large B-cell lymphoma is bo
إعجاب
علق
شارك
